Clinical Trial Update: Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating umbralisib and pembrolizumab in relapsed or refractory classical Hodgkin lymphoma was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• umbralisib

Snippet

Sponsor: University of Washington | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-05-03